Cargando…

Association of HLA-B51:01, HLA-B55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population

Phenytoin (PHT) is one of the most commonly reported aromatic anti-epileptic drugs (AEDs) to cause cutaneous adverse reactions (CADRs), particularly severe cutaneous adverse reactions (SCARs). Although human leukocyte antigen (HLA)-B*15:02 is associated with PHT-induced Steven Johnson syndrome/toxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	John, Shobana, Balakrishnan, Karuppiah, Sukasem, Chonlaphat, Anand, Tharmarajan Chinnathambi Vijay, Canyuk, Bhutorn, Pattharachayakul, Sutthiporn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400937/ https://www.ncbi.nlm.nih.gov/pubmed/34442381 http://dx.doi.org/10.3390/jpm11080737

Ejemplares similares

Identification of the novel HLA‐B*51:01:01:78 allele and confirmation of extended sequence of B*18:01:26
por: Ulrich, Silvia, et al.
Publicado: (2022)

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
por: Sukasem, Chonlaphat, et al.
Publicado: (2016)

HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions in a Thai population
por: Jantararoungtong, Thawinee, et al.
Publicado: (2014)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01
por: Pratoomwun, Jirawat, et al.
Publicado: (2021)

Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet’s uveitis
por: Kaburaki, Toshikatsu, et al.
Publicado: (2019)

Comparison between the HLA-B(∗)58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions
por: Saksit, Niwat, et al.
Publicado: (2017)

Genome-wide Study Identifies Association between HLA-B(∗)55:01 and Self-Reported Penicillin Allergy
por: Krebs, Kristi, et al.
Publicado: (2020)

Associations of HLA‐C*01:02 and HLA‐B*46:01 with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer
por: Fujita, Ken‐ichi, et al.
Publicado: (2023)

Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
por: Scholz, Erika Margaret, et al.
Publicado: (2017)

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
por: Satapornpong, Patompong, et al.
Publicado: (2021)

HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children
por: Amstutz, Ursula, et al.
Publicado: (2013)

Subacute Thyroiditis is Associated with HLA-B*18:01, -DRB1*01 and -C*04:01—The Significance of the New Molecular Background
por: Stasiak, Magdalena, et al.
Publicado: (2020)

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02
por: Martín, Paloma, et al.
Publicado: (2015)

Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice
por: El Bissati, Kamal, et al.
Publicado: (2020)

Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
por: Ade, Catherine M, et al.
Publicado: (2023)

Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis
por: Biswas, Mohitosh, et al.
Publicado: (2022)

Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex
por: Hirasawa, Makoto, et al.
Publicado: (2018)

Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey
por: Sahin, Ziver, et al.
Publicado: (2012)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis
por: Jaruthamsophon, Kanoot, et al.
Publicado: (2017)

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1
por: O'Connor, Geraldine M., et al.
Publicado: (2015)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01
por: Huan, Xuelu, et al.
Publicado: (2023)

Association between HLA-B*1502 allele and aromatic antiepileptic drugs-induced hypersensitivity syndrome reactions and the HLA-B*15:02 pharmacogenetics screening in autistic spectrum disorder
por: Sukasem, Chonlaphat, et al.
Publicado: (2014)

Effective Elicitation of Human Effector CD8(+) T Cells in HLA-B*51:01 Transgenic Humanized Mice after Infection with HIV-1
por: Sato, Yoshinori, et al.
Publicado: (2012)

Identification of an Unconventional Subpeptidome Bound to the Behçet's Disease-associated HLA-B*51:01 that is Regulated by Endoplasmic Reticulum Aminopeptidase 1 (ERAP1)
por: Chen, Liye, et al.
Publicado: (2020)

Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand
por: Tiwattanon, Kanyawan, et al.
Publicado: (2022)

HLA-B*15:02 genotype associated with hypersensitivity syndrome to lamotrigine in Thai population
por: Koomdee, Napatrupron, et al.
Publicado: (2014)

Molecular Basis of a Dominant T Cell Response to an HIV Reverse Transcriptase 8-mer Epitope Presented by the Protective Allele HLA-B*51:01
por: Motozono, Chihiro, et al.
Publicado: (2014)

ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function
por: D’Amico, Silvia, et al.
Publicado: (2021)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01
por: Salzberger, Wilhelm, et al.
Publicado: (2015)

Clinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
por: Zhang, Xinju, et al.
Publicado: (2018)

HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

Allopurinol-Induced Stevens–Johnson Syndrome in Javanese Men With Positive HLA‐B*58:01
por: Ferdiana, Astri, et al.
Publicado: (2022)

HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature
por: Liao, Jin-Mao, et al.
Publicado: (2023)

Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study
por: Manca, Maria Antonietta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ta5jun66a758jt7tvg303povp8